I-Afatinib CAS 439081-18-2 Ubunyulu > 99.5% (HPLC) Factory

Inkcazelo emfutshane:

Igama leKhemikhali: Afatinib

Izithethantonye: BIBW2992

CAS: 439081-18-2

Ubunyulu: >99.5% (HPLC)

Imbonakalo: I-Off-White Powder

E-Mail: alvin@ruifuchem.com


Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

Iipropati zeMichiza:

Igama leMchiza Afatinib
Izithethantonye BIBW2992;BIBW-2992;BIBW2992 Isiseko sasimahla;Tomtovok;(S,E)-N-(4-(3-Chloro-4-Fluorophenylamino)-7-(Tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(Dimethylamino)kodwa-2-Enamide
Inombolo yeCAS 439081-18-2
Inombolo yeCAT RF-PI2033
Ubume beStokhwe Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli I-C24H25ClFN5O3
Ubunzima beMolekyuli 485.94
Ukunyibilika Inyibilika kwi-DMSO
Ukuxinana 1.380
Uphawu Ruifu Chemical

Iinkcukacha:

Into Iinkcukacha
Imbonakalo I-Off-White Powder
Ukuchongwa I-HPLC, NMR
Ubunyulu / Indlela yokuHlalutya >99.5% (HPLC)
Indawo yokunyibilika 100.0 ~ 102.0℃
Ilahleko ekomisweni <0.50%
Intsalela kwi-Ignition <0.20%
Ukungcola ngokupheleleyo <0.50%
Iintsimbi ezinzima ≤20ppm
NMR Spectrum Iyahambelana neSakhiwo
Umgangatho woVavanyo Umgangatho woShishino
Beka ubomi kwishelufa Iinyanga ezingama-24 ukuba zigcinwe ngokufanelekileyo
Ukusetyenziswa API;Afatinib;Afatinib Dimaleate;NSCLC

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma

Izinto eziluncedo:

1

FAQ:

Isicelo:

I-Afatinib, eyaziwa ngokuba yi-BIW-2992, (i-CAS: 439081-18-2) isizukulwana sesibini esinamandla kunye nesingenakuguqulwa inhibitor ye-epidermal growth factor receptor (EGFR) kunye ne-epidermal growth factor receptor 2 (HER2) i-tyrosine kinase, iphuhliswe nguBoehringer Ingelheim, eJamani.Iyakwazi ukuvimbela ngokungenakuguqulwa umsebenzi we-tyrosine kinase ngokufumana impendulo kaMichael kunye neqela le-thiol le-cysteine ​​​​kwindawo ye-797 ye-EGFR.Ngomhla we-12 kaJulayi, i-2013, yaba lichiza elitsha lokulwa nomhlaza wemiphunga yeseli encinci evunywe yi-US FDA phantsi kwegama lezorhwebo likaGilotrif.Eli chiza yi-tablet.Isetyenziselwa unyango lwezigulana ezifunyanwe zinomhlaza wemiphunga we-metastatic ongeyonxalenye encinci yeseli (NSCLC) kunye nokulahleka kwe-19th exon okanye i-L858R utshintsho kwi-21th exon ye-tumor epidermal growth factor receptor (EGFR) eqinisekisiweyo kusetyenziswa ikiti evunyiweyo. yi-FDA.Ichiza likwasebenza kunyango lwezigulane ezine-HER2 ezinomhlaza webele ophezulu.I-Afatinib yeyeklasi yamachiza eyaziwa ngokuba yi-tyrosine kinase inhibitors.I-Tyrosine kinase inhibitors yenzelwe ukuvimba isenzo se-enzyme ethile ebizwa ngokuba yi-tyrosine kinase.Le enzyme idlala indima enkulu kumsebenzi weeseli, kwaye iyasebenza ekukhuthazeni ukukhula kwethumba kunye nokuqhubela phambili.I-Afatinib isebenza ukuvimbela umsebenzi weentlobo ezimbini ze-tyrosine kinases: i-epidermal growth factor receptor (EGFR) kunye ne-Her2, "echazwe ngokugqithiseleyo" ngeentlobo ezininzi zomhlaza.Ngokuthintela ukusebenza kwezi tyrosine kinases, i-Afatinib inokuthintela iiseli zomhlaza ekwahluleleni nasekukhuleni.

Bhala umyalezo wakho apha kwaye uwuthumele kuthi